Renaissance Technologies LLC Grows Stock Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

Renaissance Technologies LLC lifted its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 7.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,630,439 shares of the company's stock after purchasing an additional 115,939 shares during the quarter. Renaissance Technologies LLC owned about 0.79% of Cellebrite DI worth $35,919,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of CLBT. Quarry LP acquired a new stake in shares of Cellebrite DI during the third quarter valued at about $27,000. R Squared Ltd acquired a new position in Cellebrite DI during the fourth quarter worth $100,000. Polen Capital Management LLC purchased a new position in shares of Cellebrite DI during the fourth quarter worth $222,000. Victory Capital Management Inc. acquired a new stake in shares of Cellebrite DI in the fourth quarter valued at $234,000. Finally, HighTower Advisors LLC purchased a new stake in shares of Cellebrite DI in the 4th quarter valued at $274,000. 45.88% of the stock is owned by institutional investors and hedge funds.

Cellebrite DI Stock Down 1.2 %

Cellebrite DI stock traded down $0.24 during midday trading on Thursday, reaching $18.80. The company's stock had a trading volume of 168,411 shares, compared to its average volume of 1,729,789. Cellebrite DI Ltd. has a fifty-two week low of $10.24 and a fifty-two week high of $26.30. The business has a 50-day simple moving average of $19.23 and a 200-day simple moving average of $20.02. The company has a market cap of $4.50 billion, a P/E ratio of -13.51, a P/E/G ratio of 4.27 and a beta of 1.44.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. As a group, equities analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. JPMorgan Chase & Co. increased their price target on shares of Cellebrite DI from $24.00 to $28.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 11th. Needham & Company LLC reiterated a "buy" rating and set a $28.00 target price on shares of Cellebrite DI in a report on Wednesday, April 2nd. Finally, Lake Street Capital boosted their price target on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a research note on Friday, February 14th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $23.43.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.